In other recent news, Biogen has been the topic of significant developments. The biotech firm reported a total revenue of $2.5 billion in its second-quarter results. Biogen's investigational drug, felzartamab, recently received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for treating a specific type of kidney transplant rejection. Furthermore, the company's DEVOTE study suggests potential clinical benefits of a higher dose regimen of nusinersen for individuals with spinal muscular atrophy.